Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Novo Nordisk A/S (NVO)

NYSE
Symbol
Exchange
Currency
NVONYSEUSD
NOVOBcBATS EuropeDKK
0QIULondonDKK
NVONMexicoMXN
NOVGDusseldorfEUR
NOVGXetraEUR
NOVGFrankfurtEUR
NOVObCopenhagenDKK
NNO2ViennaEUR
Currency in USD
Disclaimer
125.80
-0.36(-0.29%)
Closed
After Hours
125.50-0.31(-0.24%)

NVO Comments

this company was doing so well, what happened.
Profit taking imo, it’ll go higher
A1C down from 9.4 to 6.2 and weight down from 254 to 238 with Ozempic. Lot of flatulence and air freshener.
300 by 2024
gonna dominate the obesity space with Catalent mreger
450 by 2030.. Serving 1 mill custumors now and there are 800 mill. U do the math..
NVO should advance nicely Wednesday on good earnings and a bright 2024 outlook.
Eli is very keen on disrupting NN but they dont even have cardio vascular studies or a candidate for next generation but NN dos. They are way behind so dont be disrupted by their lobby activities ….
140+ eoy
Not with the recent deaths from Ozempic.
Come with dome documentstion dude. Far out to say
like all things, eventually we will know the outcome
Now all small investors seems to fanzy ophra Winfrey to dictate the benefits and dowfalls in pharma industry. What a world with celebraties and you tupers now rules the world. S… t.. f… up woman - you dont know what you are talking about and go back to girlish problems and your billions..
But, pharma boys and girls can only continue parabolic if sick and overweight people increase....dilemma.
Something is not right here. There are probably alot of long term side effects to using ozempic for weight loss, the drug was intended to treat diabetes not weight loss keep that in mind. And we all know that taking drugs if you are healty is dangerous.
It has been testet for many years for diabetics and this is a known "side effect" (weight loss) and it seems as if this in fact is a wonder druck so no need to say bad things without knowing anything about it. Take into accoutn how many problems there are with peoples weight in this world. If we can stop people from eating as much and loose weight I cannot even begin to tell you how many lifestyle problems we wont have anymore.
Starnge Eli Lilly keeps on being mentioned in this reagrd on different platforms as if the were the benchmark in obesity relations. HALLO THEY ARE NOT EVEN ON THE MARKET YET so forget them. NN has the product and more to come so Eli is just a slow follower.
Work at novo and exited about where this adventure ends share wise. It could spike with another 50% this year alone. When have U heard about a slimming agent that actual works. This works insanly and now also improve on heart vascular diseases. Totally wonder druc..
Another Milestone is forward for this company. so happy to be loaded in Novo Nordisk.
Hi, Bros !!! It was really cool. A survey of whales like my investment propensity on a newspaper site showed a result called Jim Simmons from Renaissance Technology. What has been surprising, however, is that Novo Nordisk AS is the stock that Jim Simons holds the most. Because this was the only event I recommended to my acquaintance. It was really cool. HHH
Bidens new atrack is crazy. Proces from novo and others are lowered by 75% and the listing prices are high so we can supply big discounts. Its US insurance companies who sets these high prices to their custumers.. What a scame to put it out like that old man. Its your own system that is rotten..
Bright future for this company
ONE DAY THESE GUYS WILL CURE DIABETES
NVO offers great products. I'm long term here!!!!
Their weight loss drug is getting massive attention on social media. this is helping Novo Nordisk to sell all they can make. This stock is a major buy
novo very expensive drug market hemophilia drug big profitible business
Novo Nordisk announced plans to invest more than 17 billion Danish kroner ($2.58 billion) in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.
I'm in the middle off it (working at NN). Massive undertaking and people are rushing to this company. 30% up last year and 33% this year up the hiring
sure, best company
NVO WILL BUY ORMP AT 30 $
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.